PATRICIA ESMERALDA
CARREIRA DELGADO
Profesora asociada de Ciencias de la Salud
Hospital Universitario Virgen de las Nieves
Granada, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Virgen de las Nieves (24)
2022
-
Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis
npj Genomic Medicine, Vol. 7, Núm. 1
2020
-
A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease
Scientific Reports, Vol. 10, Núm. 1
2019
-
Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept
PLoS ONE, Vol. 14, Núm. 2
-
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways
Nature Communications, Vol. 10, Núm. 1
2018
-
Association of a rare variant of the TNFSF13B gene with susceptibility to Rheumatoid Arthritis and Systemic Lupus Erythematosus
Scientific Reports, Vol. 8, Núm. 1
-
Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis
PLoS ONE, Vol. 13, Núm. 5
2017
-
A combined large-scale meta-Analysis identifies COG6 as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus
Annals of the Rheumatic Diseases, Vol. 76, Núm. 1, pp. 286-294
2016
-
LILRA3 deficiency is not involved in the giant cell arteritis and systemic sclerosis predisposition
Clinical and Experimental Rheumatology
-
Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis
Pharmacogenomics Journal, Vol. 16, Núm. 2, pp. 137-140
2015
-
Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis
Clinical and Experimental Rheumatology, Vol. 33, pp. 31-35
-
FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors
Pharmacogenomics, Vol. 16, Núm. 4, pp. 333-345
-
Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: A case-only study
Arthritis Research and Therapy, Vol. 17, Núm. 1
2014
-
A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility
Arthritis Research and Therapy, Vol. 16, Núm. 1
-
Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis
Pharmacogenetics and Genomics, Vol. 24, Núm. 5, pp. 238-245
-
Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: A genome-wide association study replication and meta-analysis
Arthritis Research and Therapy, Vol. 16, Núm. 2
2013
-
A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci
Human Molecular Genetics, Vol. 22, Núm. 19, pp. 4021-4029
-
Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility
Annals of the Rheumatic Diseases, Vol. 72, Núm. 7, pp. 1233-1238
2012
-
Analysis of class II human leucocyte antigens in Italian and Spanish systemic sclerosis
Rheumatology, Vol. 51, Núm. 1, pp. 52-59
-
Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis
Arthritis Research and Therapy, Vol. 14, Núm. 3
-
Evaluation of a shared autoimmune disease-associated polymorphism of TRAF6 in systemic sclerosis and giant cell arteritis
Journal of Rheumatology, Vol. 39, Núm. 6, pp. 1275-1279